Finally, we looked for possible correlations between tumor microenvironment expression of COX-2, and percentage of CD4 and CD8 tumor infiltrating lymphocytes (TILs) with patient characteristics and clinical outcomes. The gene discussed is PTGS2; the disease is neoplasm.